Issuance of Equity. AEON shall issue 26,680,511 shares of Common Stock (the “Issued Shares”) to Medytox pursuant to the terms of the Share Issuance Agreement attached hereto as Exhibit A (the “Share Issuance Agreement”). Further, in the event that the Company completes an Initial Public Offering (as defined in the Share Issuance Agreement) and the Issued Shares cease to represent at least ten (10%) percent of the Company’s then-outstanding shares of capital stock immediately following the closing of such Offering, AEON shall issue to Medytox a number of additional shares of Common Stock (the “Additional Shares”) such that the Issued Shares plus such Additional Shares equal ten (10%) percent of the Company’s then-outstanding shares of capital stock immediately following the closing of the Company’s Initial Public Offering. The issuance of the Additional Shares shall be subject to Medytox entering into such additional documentation as reasonably requested by the Company.
Appears in 4 contracts
Samples: Settlement and License Agreement (AEON Biopharma, Inc.), Settlement and License Agreement (AEON Biopharma, Inc.), Settlement and License Agreement (AEON Biopharma, Inc.)